Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the microbiome differences and their effects after transplantation form different intestine areas. The results show how host-microbe mismatches after these interventions could affect gut health.
Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the microbiome differences and their effects after transplantation form different intestine areas. The results show how host-microbe mismatches after these interventions could affect gut health.
Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.
Gastric cancer, which is the fifth most frequent cancer globally and the third most frequent cause of cancer-related deaths, can be managed relatively well with existing therapies. Advanced gastric cancer, in contrast, is more difficult to manage.
Researchers have investigated the role of the voltage-dependent potassium channel Kv1.3 in vivo in a murine model of ethanol-exposed alcohol-related liver disease (ALD).
Researchers from Guangdong Pharmaceutical University and collaborators reported the discovery of [I], a novel FABP/PPAR multiple modulator aimed at the treatment of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a complex liver disease with limited treatment options.
Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus (HCV) infection and liver cancer (hepatocellular carcinoma).
RSS
